German biopharma Vivoryon Therapeutics (VVY:AEX) has announced results for its Alzheimer’s disease (AD) drug candidate varoglutamstat from the ongoing European Phase IIb study VIVIAD.
The results, presented at the Alzheimer’s Association International Conference (AAIC) being held in San Diego, California, led to shares in Vivoryon closing 16% higher on Monday.
Positive Phase IIb safety data from 181 patients showed no on-target toxicity, including at the selected therapeutic dose of 600mg given twice daily, known to result in target occupancy of nearly 90%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze